




MDH-115 for the treatment of Intractable Ocular Diseases

MDH-015 (*Micrococcus luteus* EV) is a new class of first-in-class oral therapeutic indicated for intractable ocular diseases, such as dry and wet forms of age-related macular degeneration (AMD), diabetic retinopathy, and more

MDH-115

- Naïve (natural) EVs from a single **Micrococcus** strain



Value Propositions

1. **First-in-class**: a new modality drug with a novel mechanism of action (MoA)
2. **Very safe**: a safe soil bacterium *Micrococcus luteus*-derived EVs
3. **Effective**: a disease-modifying therapy against intractable ocular diseases, including dry AMD, wet AMD, & diabetic retinopathy (DR)
4. **Convenient administration**: orally-delivered
5. **Affordable**: cost effective production

MDH-115: Key Indications & Development Timeline

Key Indications

- 1) **Dry AMD (age-related macular degeneration)**
- 2) **Wet AMD (age-related macular degeneration)**
- 3) **Diabetic retinopathy (DR)**

Core patents

1. Core patent (1)
 - ✓ PCT (KR2019/002341) application date at 27/Feb/2019
 - ✓ Registered at KR, US (as of July 2022)
2. Core patent (2)
 - ✓ PCT (KR2021/014598) application date at 19/Oct/2021

Development Timeline

IND filing ('23)



P1 ('24)



P2 ('26)



Exit